Biotech | October 29, 2021
Merck expands capacity for Antibody Drug Conjugate (ADC), therapies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Acute therapies continue to report strong growth compared to chronic ones.
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Second interchangeable biosimilar product approved by agency
Subscribe To Our Newsletter & Stay Updated
